MAP2K7 and neoplasm: In the most recent study, MEK inhibitors alone were ineffective, but low-dose combinations of a MEK inhibitor (mirdametinib) and CDK4/6 inhibitor (palbociclib) acted synergistically in causing remarkable tumor regression and improved survival in immune competent mice bearing MPNSTs [105].